O. Bulbul Et Al. , "Factors affecting overall survival and progression-free survival in patients with metastatic castration resistant prostate cancer received Lu-177 PSMA I&T therapy," HELLENIC JOURNAL OF NUCLEAR MEDICINE , vol.23, no.3, pp.229-239, 2020
Bulbul, O. Et Al. 2020. Factors affecting overall survival and progression-free survival in patients with metastatic castration resistant prostate cancer received Lu-177 PSMA I&T therapy. HELLENIC JOURNAL OF NUCLEAR MEDICINE , vol.23, no.3 , 229-239.
Bulbul, O., ÜNEK, İ. T., KEFİ, A., TUNA, E. B., & BEKİŞ, R., (2020). Factors affecting overall survival and progression-free survival in patients with metastatic castration resistant prostate cancer received Lu-177 PSMA I&T therapy. HELLENIC JOURNAL OF NUCLEAR MEDICINE , vol.23, no.3, 229-239.
Bulbul, Ogun Et Al. "Factors affecting overall survival and progression-free survival in patients with metastatic castration resistant prostate cancer received Lu-177 PSMA I&T therapy," HELLENIC JOURNAL OF NUCLEAR MEDICINE , vol.23, no.3, 229-239, 2020
Bulbul, Ogun Et Al. "Factors affecting overall survival and progression-free survival in patients with metastatic castration resistant prostate cancer received Lu-177 PSMA I&T therapy." HELLENIC JOURNAL OF NUCLEAR MEDICINE , vol.23, no.3, pp.229-239, 2020
Bulbul, O. Et Al. (2020) . "Factors affecting overall survival and progression-free survival in patients with metastatic castration resistant prostate cancer received Lu-177 PSMA I&T therapy." HELLENIC JOURNAL OF NUCLEAR MEDICINE , vol.23, no.3, pp.229-239.
@article{article, author={Ogun Bulbul Et Al. }, title={Factors affecting overall survival and progression-free survival in patients with metastatic castration resistant prostate cancer received Lu-177 PSMA I&T therapy}, journal={HELLENIC JOURNAL OF NUCLEAR MEDICINE}, year=2020, pages={229-239} }